ImmunityBio
IBRX
6.02
-0.55
-8.37%
ImmunityBio
US · IBRX
#1397 by market cap
Listed 1970
6.02
-0.55
-8.37%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:59
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 10 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 53.29% -0.05pp
- Institutions
- 459 +10
- As of
- 2026/Q3 vs. prior period
Holder types
Individual/Insider27.79%
VC/PE Fund24.35%
Mutual Fund14.61%
Private Company9.51%
Hedge Fund3.43%
Public Company1.03%
Government Pension Fund0.17%
Family Office/Trust0.11%
Other18.93%
Top holders as of 2026-07-31
Patrick Soon-Shiong
27.40% · 291.46M sh
California Capital Equity, LLC
24.35% · 259.00M sh
NantWorks, LLC
9.26% · 98.54M sh
BlackRock
3.40% · 36.12M sh
State Street Global Advisors
1.99% · 21.10M sh
Vanguard Portfolio Management, LLC
1.82% · 19.39M sh
Vanguard Capital Management, LLC
1.77% · 18.80M sh
D. E. Shaw & Co., L.P.
1.09% · 11.55M sh
Two Sigma Investments, LP
1.04% · 11.10M sh
Geode Capital Management, LLC
1.00% · 10.61M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 21 buys · 29 sells
| Name | Role | Stake |
|---|---|---|
| Patrick Soon-Shiong | Founder, Executive Chairman and Global Chief Scientific & Medical Officer | 27.40% |
| California Capital Equity, LLC | -- | 24.35% |
| Barry Simon | Chief Corporate Affairs Officer & Director | 0.26% |
| Richard Adcock | Chief Executive Officer | 0.05% |
| David Sachs | Chief Financial Officer | 0.03% |
| Michael Blaszyk | Independent Director | 0.02% |
| Regan Lauer | Chief Accounting Officer | 0.01% |
| Cheryl Cohen | Lead Independent Director | 0.01% |
| John Brennan | Former Independent Director | 0.00% |
| Wesley Clark | Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-04 | Barry Simon | Chief Corporate Affairs Officer & Director | Automatic Disposition | -25,000 | $10.75 |
| 2026-10-04 | Barry Simon | Chief Corporate Affairs Officer & Director | Intent to Sell (Form 144) | -560,000 | $13.67 |
| 2026-10-01 | Cheryl Cohen | Lead Independent Director | Automatic Disposition | -25,077 | $10.50 |
| 2026-10-01 | Cheryl Cohen | Lead Independent Director | Derivative Exercise and Sale | -55,979 | $2.98–10.50 |
| 2026-07-01 | Cheryl Cohen | Lead Independent Director | Automatic Disposition | -75,231 | $9.50 |
| 2026-07-01 | Cheryl Cohen | Lead Independent Director | Derivative Exercise and Sale | -55,979 | $2.98–9.50 |
| 2026-06-30 | Christobel Selecky | Independent Director | Derivative Exercise and Sale | -159,478 | $2.98–9.02 |
| 2026-06-29 | Christobel Selecky | Independent Director | Derivative Exercise and Sale | -96,722 | $2.84–9.01 |
| 2026-06-29 | Christobel Selecky | Independent Director | Intent to Sell (Form 144) | -1,000 | $8.77 |
| 2026-06-28 | Christobel Selecky | Independent Director | Intent to Sell (Form 144) | -95,722 | $8.71 |
| 2026-06-23 | Barry Simon | Chief Corporate Affairs Officer & Director | Automatic Disposition | -25,000 | $7.88 |
| 2026-06-08 | Christobel Selecky | Independent Director | Other Derivative Acquisition | +65,600 | $7.25 |
| 2026-06-08 | Wesley Clark | Independent Director | Other Derivative Acquisition | +65,600 | $7.25 |
| 2026-06-08 | Bruce Wendel | Independent Director | Other Derivative Acquisition | +65,600 | $7.25 |
| 2026-06-08 | Michael Blaszyk | Independent Director | Other Derivative Acquisition | +65,600 | $7.25 |
| 2026-06-08 | Cheryl Cohen | Lead Independent Director | Other Derivative Acquisition | +65,600 | $7.25 |
| 2026-06-08 | Linda Maxwell | Independent Director | Other Derivative Acquisition | +65,600 | $7.25 |
| 2026-06-03 | Barry Simon | Chief Corporate Affairs Officer & Director | Automatic Disposition | -23,033 | $7.18 |
| 2026-03-30 | California Capital Equity, LLC | -- | Derivative Exercise and Retained | +4,606,596 | $5.43 |
| 2026-02-23 | Barry Simon | Chief Corporate Affairs Officer & Director | Automatic Disposition | -75,000 | $12.01 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:59:40 · For reference only, not investment advice and not tailored to your situation.
ImmunityBio discussion 0 comments